Table 1.
Baseline characteristics of participants with acute HIV infection stratified by treatment arm.
| Characteristics | VHMa + ARTb (N = 10) | ARTb only (N = 5) |
|---|---|---|
| Acute HIV infection stage at ART initiation |
8 Fiebig III/2 Fiebig IV |
5 Fiebig III |
| Gender (Male: Female) |
9:1 |
4:1 |
| Viral load at ART initiation, log10 copies/mL |
6.1 (4.7–7.5) |
5.6 (3.1–7.1) |
| CD4+ T cells/μL at ART initiation |
397 (132–574) |
532 (213–740) |
| CD4: CD8 ratio at ART initiation |
0.4 (0.3–2.1) |
0.8 (0.6–1.0) |
| Total HIV DNA at ART initiation, copies/106 PBMC |
837 (0.8–2,323) |
594 (19–1,878) |
| Length of time on ART prior to trial entry, weeks |
224 (79–294) |
155 (100–295) |
| ART at trial entry | ||
| EFVc/TDFd/FTCe | 5 | 4 |
| EFV/TDF/3 TCf | 1 | 0 |
| LPV-rg/TDF/FTC | 3 | 0 |
| RALh/TDF/3 TC |
1 |
1 |
| Age at trial entry, years |
28 (22–51) |
26 (24–34) |
| Plasma HIV RNA at trial entry, log10 copies/mL |
<1.3 |
<1.3 |
| CD4+ T cells/μL at trial entry |
634 (501–1,106) |
1079 (537–1,612) |
| CD4: CD8 ratio at trial entry |
1.2 (0.7–2.6) |
1.2 (0.8–1.4) |
| Total HIV DNA at trial entry, copies/106 PBMC | 5.5 (0.8–93.0) | 27.0 (3.0–86.0) |
Data are presented as Median (Minimum-Maximum) unless otherwise specified.
a
VHM: vorinostat/hydroxychloroquine/maraviroc.
b
ART: antiretroviral therapy.
c
EFV: efavirenz.
d
TDF: tenofovir.
e
FTC: emtricitabine.
f
3TC: lamivudine.
g
LPV-r: ritonavir boosted lopinavir.
h
RAL: raltegravir.